Benefit versus risk of chromosomal microarray analysis performed in pregnancies with normal and positive prenatal screening results: A retrospective study
Open Access
- 26 April 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (4) , e0250734
Abstract
Background: Most studies on chromosomal microarray analysis (CMA) and amniocentesis risks have not evaluated pregnancies with low risk for genetic diseases; therefore, the efficacy and safety of CMA and amniocentesis in this population are unclear. This study aimed to examine the benefits and risks of prenatal genetic diagnostic tests in pregnancies having low risk for chromosomal diseases.Methods and findings: In this retrospective study, we used clinical data from a large database of 30,830 singleton pregnancies at gestational age 16–23 weeks who underwent amniocentesis for karyotyping with or without CMA. We collected socio-demographic, medical and obstetric information, along with prenatal screening, CMA and karyotyping results. Fetal loss events were also analysed. CMA was performed in 5,837 pregnancies with normal karyotype (CMA cohort). In this cohort, 4,174 women had normal prenatal screening results and the risk for identifying genetic abnormalities with >10% risk for intellectual disability by CMA was 1:102, with no significant difference between maternal age groups. The overall post-amniocentesis fetal loss rate was 1:1,401 for the entire cohort (n = 30,830) and 1:1,945 for the CMA cohort (n = 5,837). The main limitation of this study is the relatively short follow-up of 3 weeks, which may not have been sufficient for detecting all fetal loss events.Conclusion: The low risk for post-amniocentesis fetal loss, compared to the rate of severe genetic abnormalities detected by CMA, suggests that even pregnant women with normal prenatal screening results should consider amniocentesis with CMA.Keywords
Funding Information
- The Adler Chair of the Sackler School of Medicine, Tel-Aviv University
This publication has 28 references indexed in Scilit:
- Amniocentesis and chorionic villus sampling for prenatal diagnosisCochrane Database of Systematic Reviews, 2017
- First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screeningCochrane Database of Systematic Reviews, 2017
- Practice Bulletin No. 162Obstetrics & Gynecology, 2016
- Chromosomal Microarray Analysis (CMA) a Clinical Diagnostic Tool in the Prenatal and Postnatal Settings.2015
- Chromosomal Microarray Analysis and Prenatal DiagnosisObstetrical & Gynecological Survey, 2014
- Procedure‐related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta‐analysisUltrasound in Obstetrics & Gynecology, 2014
- Increasing Rates of Prenatal Testing among Jewish and Arab Women in Israel over One DecadePublic Health Genomics, 2014
- Multicenter study of first‐trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk‐orientated two‐stage first‐trimester screeningUltrasound in Obstetrics & Gynecology, 2005
- UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestationThe Lancet, 1998
- RANDOMISED CONTROLLED TRIAL OF GENETIC AMNIOCENTESIS IN 4606 LOW-RISK WOMENThe Lancet, 1986